Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H19NO4 |
Molecular Weight | 337.3692 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C(=C(CCC(O)=O)C#N)C2=CC=C(OC)C=C2
InChI
InChIKey=GRVCTHTXJDYIHB-UHFFFAOYSA-N
InChI=1S/C20H19NO4/c1-24-17-8-3-14(4-9-17)20(16(13-21)7-12-19(22)23)15-5-10-18(25-2)11-6-15/h3-6,8-11H,7,12H2,1-2H3,(H,22,23)
Molecular Formula | C20H19NO4 |
Molecular Weight | 337.3692 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Satigrel (previously known as E5510) was developed as an antithrombotic agent. Satigrel antagonized platelet activation by inhibiting phospholipase C and/or A2, which results in suppression of both phosphatidylinositol breakdown and arachidonic acid release from phospholipids, as well as by inhibiting cyclooxygenase. Satigrel was studied in patients with intermittent claudication due to arteriosclerosis obliterans, where the drug improved the cutaneous circulation and symptoms of patients. In addition, the therapeutic effect of satigrel was studied on biopsy-proven chronic rejection after kidney transplantation. Also was shown that the drug had a clinical benefit over aspirin for the treatment of transient ischemic attacks. However, all these studied were apparently discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9063033
After giving informed consent and one week wash-out of effected agents, a 2 mg oral dose of satigrel twice daily was administered for more than 4 weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:26:30 GMT 2023
by
admin
on
Sat Dec 16 17:26:30 GMT 2023
|
Record UNII |
XPV71VQL72
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1248
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
C73156
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107466
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
100000084080
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
XPV71VQL72
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
C054678
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
111753-73-2
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
6944
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
DTXSID00149721
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
SUB10458MIG
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY | |||
|
65913
Created by
admin on Sat Dec 16 17:26:30 GMT 2023 , Edited by admin on Sat Dec 16 17:26:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |